Clifton Earl Barry (Clifton E Barry)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 36

Top Venues

Nature medicine

Nature communications

ACS infectious diseases

Proceedings of the National Academy of Sciences of the United States of America

National Institute of Allergy and Infectious Diseases

Cornell University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

National Institute of Allergy and Infectious Diseases Jul 01 1991

United States

Section Chief :: Laboratory of Clinical Infectious Diseases

Johns Hopkins University Jun 01 1989 - Jul 01 1991

United States

Postdoctoral Fellow :: Chemistry

Education History

Cornell University Aug 01 1985 - May 01 1989

United States

PHD :: Chemistry

University of Arizona May 01 1981 - May 01 1985

United States

BSC :: Chemistry

Publications

Meenal Datta, Laura E Via, Veronique Anne Dartois, Danielle M Weiner, Matthew Zimmerman, Firat Kaya, April M Walker, Joel D Fleegle, Isaac D Raplee, Colton McNinch, Maksym Zarodniuk, Walid S Kamoun, Changli Yue, Ashwin Srinivasan Kumar, Sonu Subudhi, Lei Xu, Clifton Earl Barry, Rakesh K Jain
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits. Proceedings of the National Academy of Sciences of the United States of America 121 (14) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
R M Naseer Khan, Yong-Mo Ahn, Gwendolyn A Marriner, Laura E Via, Francois D'Hooge, Seung Seo Lee, Nan Yang, Falguni Basuli, Alexander G White, Jaime A Tomko, L James Frye, Charles A Scanga, Danielle M Weiner, Michelle L Sutphen, Daniel M Schimel, Emmanuel Dayao, Michaela K Piazza, Felipe Gomez, William Dieckmann, Peter Herscovitch, N Scott Mason, Rolf Swenson, Dale O Kiesewetter, Keriann M Backus, Yiqun Geng, Ritu Raj, Daniel Clive Anthony, Joanne L Flynn, Clifton Earl Barry, Benjamin G Davis
Distributable, metabolic PET reporting of tuberculosis. Nature communications 15 (1) (2024)
R M Naseer Khan, Yong-Mo Ahn, Gwendolyn A Marriner, Laura E Via, Francois D'Hooge, Seung Seo Lee, Nan Yang, Falguni Basuli, Alexander G White, Jaime A Tomko, L James Frye, Charles A Scanga, Danielle M Weiner, Michelle L Sutphen, Daniel M Schimel, Emmanuel Dayao, Michaela K Piazza, Felipe Gomez, William Dieckmann, Peter Herscovitch, N Scott Mason, Rolf Swenson, Dale O Kiesewetter, Keriann M Backus, Yiqun Geng, Ritu Raj, Daniel Clive Anthony, Joanne L Flynn, Clifton Earl Barry, Benjamin G Davis
Distributable, metabolic PET reporting of tuberculosis. Nature communications 15 (1) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Helena I Boshoff, Neha Malhotra, Clifton Earl Barry, Sangmi Oh
The Antitubercular Activities of Natural Products with Fused-Nitrogen-Containing Heterocycles. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Meenal Datta, Laura E Via, Veronique Anne Dartois, Danielle M Weiner, Matthew Zimmerman, Firat Kaya, April M Walker, Joel D Fleegle, Isaac D Raplee, Colton McNinch, Maksym Zarodniuk, Walid S Kamoun, Changli Yue, Ashwin Srinivasan Kumar, Sonu Subudhi, Lei Xu, Clifton Earl Barry, Rakesh K Jain
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits. Proceedings of the National Academy of Sciences of the United States of America 121 (14) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine (2024)
Helena I Boshoff, Neha Malhotra, Clifton Earl Barry, Sangmi Oh
The Antitubercular Activities of Natural Products with Fused-Nitrogen-Containing Heterocycles. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Meenal Datta, Laura E Via, Veronique Anne Dartois, Danielle M Weiner, Matthew Zimmerman, Firat Kaya, April M Walker, Joel D Fleegle, Isaac D Raplee, Colton McNinch, Maksym Zarodniuk, Walid S Kamoun, Changli Yue, Ashwin Srinivasan Kumar, Sonu Subudhi, Lei Xu, Clifton Earl Barry, Rakesh K Jain
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits. Proceedings of the National Academy of Sciences of the United States of America 121 (14) (2024)
Meenal Datta, Laura E Via, Veronique Anne Dartois, Danielle M Weiner, Matthew Zimmerman, Firat Kaya, April M Walker, Joel D Fleegle, Isaac D Raplee, Colton McNinch, Maksym Zarodniuk, Walid S Kamoun, Changli Yue, Ashwin Srinivasan Kumar, Sonu Subudhi, Lei Xu, Clifton Earl Barry, Rakesh K Jain
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits. Proceedings of the National Academy of Sciences of the United States of America 121 (14) (2024)
R M Naseer Khan, Yong-Mo Ahn, Gwendolyn A Marriner, Laura E Via, Francois D'Hooge, Seung Seo Lee, Nan Yang, Falguni Basuli, Alexander G White, Jaime A Tomko, L James Frye, Charles A Scanga, Danielle M Weiner, Michelle L Sutphen, Daniel M Schimel, Emmanuel Dayao, Michaela K Piazza, Felipe Gomez, William Dieckmann, Peter Herscovitch, N Scott Mason, Rolf Swenson, Dale O Kiesewetter, Keriann M Backus, Yiqun Geng, Ritu Raj, Daniel Clive Anthony, Joanne L Flynn, Clifton Earl Barry, Benjamin G Davis
Distributable, metabolic PET reporting of tuberculosis. Nature communications 15 (1) (2024)
Helena I M Boshoff, Katherine Young, Yong-Mo Ahn, Veena D Yadav, Brendan M Crowley, Lihu Yang, Jing Su, Sangmi Oh, Kriti Arora, Jenna Andrews, Michelle Manikkam, Michelle Sutphin, Anthony J Smith, Danielle M Weiner, Michaela K Piazza, Joel D Fleegle, Felipe Gomez, Emmannual K Dayao, Brendan Prideaux, Matthew Zimmerman, Firat Kaya, Jansy Sarathy, Vee Yang Tan, Laura E Via, Richard Tschirret-Guth, Anne J Lenaerts, Gregory T Robertson, Veronique Anne Dartois, David B Olsen, Clifton Earl Barry
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities. ACS infectious diseases (2024)
Helena I M Boshoff, Katherine Young, Yong-Mo Ahn, Veena D Yadav, Brendan M Crowley, Lihu Yang, Jing Su, Sangmi Oh, Kriti Arora, Jenna Andrews, Michelle Manikkam, Michelle Sutphin, Anthony J Smith, Danielle M Weiner, Michaela K Piazza, Joel D Fleegle, Felipe Gomez, Emmannual K Dayao, Brendan Prideaux, Matthew Zimmerman, Firat Kaya, Jansy Sarathy, Vee Yang Tan, Laura E Via, Richard Tschirret-Guth, Anne J Lenaerts, Gregory T Robertson, Veronique Anne Dartois, David B Olsen, Clifton Earl Barry
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities. ACS infectious diseases 10 (5) (2024)
Helena I M Boshoff, Katherine Young, Yong-Mo Ahn, Veena D Yadav, Brendan M Crowley, Lihu Yang, Jing Su, Sangmi Oh, Kriti Arora, Jenna Andrews, Michelle Manikkam, Michelle Sutphin, Anthony J Smith, Danielle M Weiner, Michaela K Piazza, Joel D Fleegle, Felipe Gomez, Emmannual K Dayao, Brendan Prideaux, Matthew Zimmerman, Firat Kaya, Jansy Sarathy, Vee Yang Tan, Laura E Via, Richard Tschirret-Guth, Anne J Lenaerts, Gregory T Robertson, Veronique Anne Dartois, David B Olsen, Clifton Earl Barry
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities. ACS infectious diseases 10 (5) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
R M Naseer Khan, Yong-Mo Ahn, Gwendolyn A Marriner, Laura E Via, Francois D'Hooge, Seung Seo Lee, Nan Yang, Falguni Basuli, Alexander G White, Jaime A Tomko, L James Frye, Charles A Scanga, Danielle M Weiner, Michelle L Sutphen, Daniel M Schimel, Emmanuel Dayao, Michaela K Piazza, Felipe Gomez, William Dieckmann, Peter Herscovitch, N Scott Mason, Rolf Swenson, Dale O Kiesewetter, Keriann M Backus, Yiqun Geng, Ritu Raj, Daniel Clive Anthony, Joanne L Flynn, Clifton Earl Barry, Benjamin G Davis
Distributable, metabolic PET reporting of tuberculosis. Nature communications 15 (1) (2024)
Andreas H Diacon, Clifton Earl Barry, Alex Carlton, Ray Y Chen, Matt Davies, Veronique de Jager, Kim Fletcher, Gavin C K W Koh, Irina Kontsevaya, Jan Heyckendorf, Christoph Lange, Maja Reimann, Sophie L Penman, Rhona Scott, Gareth Maher-Edwards, Simon Tiberi, Georgios Vlasakakis, Caryn M Upton, David Barros Aguirre
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature medicine 30 (3) (2024)
Hanif Esmail, Anna K Coussens, Friedrich Thienemann, Bianca Sossen, Sandra L Mukasa, James M Warwick, Rene T Goliath, Nashreen Omar Davies, Emily Douglass, Amanda Jackson, Francisco Lakay, Elizabeth M Streicher, Jacob E Munro, Marilou H Barrios, Torben Heinsohn, Liana Macpherson, Dylan Sheerin, Saalikha Aziz, Keboile Serole, Remy Daroowala, Arshad Taliep, Petri Ahlers, Stephanus T Malherbe, Rory Bowden, Robin Mark Warren, Katharina Ronacher, Laura E Via, Melanie Bahlo, Karen Rita Jacobson, Charles R Horsburgh, Padmini Salgame, David Alland, Clifton Earl Barry, Joanne L Flynn, Jerrold J Ellner, Robert John Wilkinson
High resolution imaging and five-year tuberculosis contact outcomes. medRxiv : the preprint server for health sciences (2023)
Christoph Lange, Clifton Earl Barry, Charles R Horsburgh
Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel. American journal of respiratory and critical care medicine 205 (10) (2022)
Bree B Aldridge, David Barros-Aguirre, Clifton Earl Barry, Robert H Bates, Steven J Berthel, Helena I M Boshoff, Kelly Chibale, Xin-Jie Chu, Christopher B Cooper, Veronique Anne Dartois, Ken Duncan, Nader Fotouhi, Fabian Gusovsky, Philip A Hipskind, Dale J Kempf, Joël Lelièvre, Anne J Lenaerts, Case W MacNamara, Valerie Mizrahi, Carl Nathan, David B Olsen, Tanya Parish, H Michael Petrassi, Alexander Pym, Kyu Y Rhee, Gregory T Robertson, Jeremy Michael Rock, Eric J Rubin, Betsy Russell, David G Russell, James C Sacchettini, Dirk Schnappinger, Michael Schrimpf, Anna M Upton, Peter Warner, Paul Graham Wyatt, Ying Yuan
The Tuberculosis Drug Accelerator at year 10: what have we learned? Nature medicine 27 (8) (2021)
Sangmi Oh, M Daben J Libardo, Shaik Azeeza, Gary T Pauly, Jose Santinni O Roma, Andaleeb Sajid, Yoshitaka Tateishi, Caroline Duncombe, Michael Goodwin, Thomas R Ioerger, Paul G Wyatt, Peter C Ray, David W Gray, Helena I M Boshoff, Clifton Earl Barry
Structure-Activity Relationships of Pyrazolo[1,5-a]pyrimidin-7(4H)-ones as Antitubercular Agents. ACS infectious diseases 7 (2) (2021)
Vitor Mendes, Simon R Green, Joanna C Evans, Jeannine Hess, Michal Blaszczyk, Christina Spry, Owain Bryant, James Cory-Wright, Daniel S-H Chan, Pedro H M Torres, Zhe Wang, Navid Nahiyaan, Sandra O'Neill, Sebastian Damerow, John Post, Tracy Bayliss, Sasha L Lynch, Anthony G Coyne, Peter C Ray, Chris Abell, Kyu Y Rhee, Helena I M Boshoff, Clifton Earl Barry, Valerie Mizrahi, Paul G Wyatt, Thomas L Blundell
Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site. Nature communications 12 (1) (2021)
Andrea C Carpenter, Ehydel Castro, Zhidong Hu, Artur Trancoso Lopo de Queiroz, Claire E Tocheny, Maike Assmann, Daniel L Barber, Christine E Nelson, Paul J Baker, Hui Ma, Lin Wang, Wen Zilu, Elsa Du Bruyn, Catherine Riou, Keith D Kauffman, null null, Ian N Moore, Franca Del Nonno, Linda Petrone, Delia Goletti, Adrian R Martineau, David M Lowe, Mark R Cronan, Robert John Wilkinson, Clifton Earl Barry, Laura E Via, Daniel L Barber, Amy D Klion, Bruno Bezerril Andrade, Yanzheng Song, Ka-Wing Wong, Katrin D Mayer-Barber
Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. The Journal of experimental medicine 218 (10) (2021)
Benjamin Ruf, Vanessa V Catania, Simon Wabitsch, Chi Ma, Laurence P Diggs, Qianfei Zhang, Bernd Heinrich, Varun Subramanyam, Linda L Cui, Marie Pouzolles, Christine N Evans, Raj Chari, Shunsuke Sakai, Sangmi Oh, Clifton Earl Barry, Daniel L Barber, Tim F Greten
Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. Cancer immunology research 9 (9) (2021)
Clifton Earl Barry, Katrin D Mayer-Barber
Signature required: The transcriptional response to tuberculosis. The Journal of experimental medicine 218 (12) (2021)
Yingda L Xie, Veronique R de Jager, Ray Y Chen, Lori E Dodd, Praveen Paripati, Laura E Via, Dean A Follmann, Jing Wang, Keith Lumbard, Saher Lahouar, Stephanus T Malherbe, Jenna Andrews, Xiang Yu, Lisa C Goldfeder, Ying Cai, Kriti Arora, Andre G Loxton, Naadira Vanker, Michael Duvenhage, Jill Winter, Taeksun Song, Gerhard Walzl, Andreas H Diacon, Clifton Earl Barry
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Science translational medicine 13 (579) (2021)
Qinglan Wang, Helena I M Boshoff, Justin R Harrison, Peter C Ray, Simon R Green, Paul G Wyatt, Clifton Earl Barry
PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosis. Science (New York, N.Y.) 367 (6482) (2020)
Tiago Beites, Kathryn O'Brien, Divya Tiwari, Curtis A Engelhart, Shaun Walters, Jenna Andrews, Hee-Jeong Yang, Michelle L Sutphen, Danielle M Weiner, Emmanuel K Dayao, Matthew Zimmerman, Brendan Prideaux, Prashant V Desai, Thierry Masquelin, Laura E Via, Véronique Dartois, Helena I M Boshoff, Clifton Earl Barry, Sabine Ehrt, Dirk Schnappinger
Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development. Nature communications 10 (1) (2019)
Zhe Wang, Vijay Soni, Gwendolyn Marriner, Takushi Kaneko, Helena I M Boshoff, Clifton Earl Barry, Kyu Y Rhee
Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline. Proceedings of the National Academy of Sciences of the United States of America 116 (39) (2019)
Natasha Strydom, Sneha V Gupta, William S Fox, Laura E Via, Hyeeun Bang, Myungsun Lee, Seokyong Eum, Tae Sun Shim, Clifton Earl Barry, Matthew Zimmerman, Veronique Anne Dartois, Radojka M Savic
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. PLoS medicine 16 (4) (2019)
Katharina Kolbe, Sri Kumar Veleti, Emma E Johnson, Young-Woo Cho, Sangmi Oh, Clifton Earl Barry
Role of Chemical Biology in Tuberculosis Drug Discovery and Diagnosis. ACS infectious diseases 4 (4) (2018)
Sangmi Oh, Yumi Park, Curtis A Engelhart, Joshua B Wallach, Dirk Schnappinger, Kriti Arora, Michelle Manikkam, Brian Gac, Hongwu Wang, Nicholas Murgolo, David B Olsen, Michael Goodwin, Michelle Sutphin, Danielle M Weiner, Laura E Via, Helena I M Boshoff, Clifton Earl Barry
Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase. Journal of medicinal chemistry 61 (22) (2018)
Dinakaran Murugesan, Peter C Ray, Tracy Bayliss, Gareth A Prosser, Justin R Harrison, Kirsteen Green, Candice Soares de Melo, Tzu-Shean Feng, Leslie J Street, Kelly Chibale, Digby F Warner, Valerie Mizrahi, Ola Epemolu, Paul Scullion, Lucy Ellis, Jennifer Riley, Yoko Shishikura, Liam Ferguson, Maria Osuna-Cabello, Kevin D Read, Simon R Green, Dirk A Lamprecht, Peter M Finin, Adrie J C Steyn, Thomas R Ioerger, Jim Sacchettini, Kyu Y Rhee, Kriti Arora, Clifton Earl Barry, Paul G Wyatt, Helena I M Boshoff
2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. ACS infectious diseases 4 (6) (2018)

Clifton Earl Barry.css-eqlu8i{font-size:small;padding-left:4px;} (Clifton E Barry)

Publication Activity (10 Years)

Top Topics

Top Venues

Clifton Earl Barry (Clifton E Barry)